From #EuroPCR 2024, this @TCTMD interview between Drs. Sam Dawkins and @MattiAdam_MD examines new innovations in #TAVR with the Jenavalve Trilogy System, the only device with a CE Mark for patients with severe aortic regurgitation. Check it out below! https://lnkd.in/g3vkePDe
JenaValve Technology, Inc.
Medical Equipment Manufacturing
Irvine, CA 7,958 followers
Aortic regurgitation is different. So is our valve.
About us
JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.
- Website
-
http://www.jenavalve.com
External link for JenaValve Technology, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Irvine, CA
- Type
- Privately Held
- Founded
- 2013
Locations
-
Primary
Get directions
4 Cromwell
Suite 100
Irvine, CA 92618, US
Employees at JenaValve Technology, Inc.
Updates
-
The results of the ALIGN-AR Trial are here! As published in @TheLancet, the primary safety and efficacy endpoints were met in 180 patients with moderate-to-severe or severe AR treated with the Trilogy System. See the data here: https://lnkd.in/gGsvGFXd
Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study
sciencedirect.com
-
#NYValves is a wrap! Thank you @crfheart for an incredible inaugural meeting – the need for a dedicated #TAVR valve for #AorticRegurgitation is clearer than ever... and the anticipation is growing!
-
-
Join us at 3:40 in Room 405 for a live case from The Heart Center in Copenhagen – the case will feature the Trilogy Valve - a dedicated #TAVR device for #AorticRegurgitation. #NYValves2024 🫀
-
Are you in New York for #NYValves2024? Don't miss our satellite program “A Forward Outlook on TAVR for Aortic Regurgitation” where we will learn from the experts on: 🩻 Imaging methods for AR 🫀 ALIGN-AR Trial updates 🌍 Real-world EU experience with JenaValve Trilogy System Add this important session to your calendar now so that you don’t miss it: https://lnkd.in/gz9JJgup
-
Join us on Wednesday at #NYValves2024 for a very important academic satellite program on the future of #TAVR for #AorticRegurgitation. You can pre-register here ➡️ https://lnkd.in/gyRpS4MJ
-
-
#NYValves2024 is just around the corner!🫀 Join us for an amazing program, filled with exceptional cases, lectures and presentations on #TAVR for #AorticRegurgitation. Together, we can address a significant unmet need in #ValveDisease. See you there!
-
Last day of #EUROPCR 2024 is here! Be sure to visit us at Booth M72 and don't miss your chance to explore the latest advancements in #TAVR for #AorticRegurgitation.
-
Today marks the start of #EUROPCR 2024! Come join us at Booth M72 from now until May 17th to delve into the latest developments in #TAVR for #AorticRegurgitation. We look forward to seeing you there!
-
#EUROPCR 2024 is almost here! Visit us at Booth M72 from May 14th to 17th to learn about the latest advancements in #TAVR for #AorticRegurgitation. See you there! @PCRonline